Dynavax Technologies Corporation (DVAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dynavax Technologies Corporation (DVAX) has a cash flow conversion efficiency ratio of 0.063x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($33.83 Million) by net assets ($534.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Dynavax Technologies Corporation stock valuation for the company's overall valuation and market capitalisation.
Dynavax Technologies Corporation - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Dynavax Technologies Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dynavax Technologies Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dynavax Technologies Corporation ranked by their cash flow conversion efficiency. Explore earnings quality score of Dynavax Technologies Corporation to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guizhou Redstar Developing Co Ltd
SHG:600367
|
0.010x |
|
Beijing Ctrowell Technology Corp Ltd
SHE:300455
|
0.038x |
|
Wedge Industrial Co Ltd
SHE:000534
|
0.006x |
|
Chongqing Three Gorges Water Conservancy and Electric Power Co Ltd
SHG:600116
|
0.048x |
|
I-Chiun Precision Industry Co Ltd
TW:2486
|
0.023x |
|
Semapa
LS:SEM
|
0.059x |
|
Xiamen ITG Group Corp Ltd
SHG:600755
|
0.080x |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
-0.046x |
Annual Cash Flow Conversion Efficiency for Dynavax Technologies Corporation (2002–2024)
The table below shows the annual cash flow conversion efficiency of Dynavax Technologies Corporation from 2002 to 2024. View DVAX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $596.80 Million | $66.51 Million | 0.111x | -31.06% |
| 2023-12-31 | $622.07 Million | $100.56 Million | 0.162x | +49.76% |
| 2022-12-31 | $581.01 Million | $62.72 Million | 0.108x | -92.85% |
| 2021-12-31 | $222.37 Million | $335.53 Million | 1.509x | +196.00% |
| 2020-12-31 | $58.69 Million | $-92.25 Million | -1.572x | +89.25% |
| 2019-12-31 | $8.29 Million | $-121.25 Million | -14.626x | -602.51% |
| 2018-12-31 | $63.06 Million | $-131.30 Million | -2.082x | -435.95% |
| 2017-12-31 | $199.55 Million | $-77.52 Million | -0.388x | +67.63% |
| 2016-12-31 | $89.20 Million | $-107.05 Million | -1.200x | -142.56% |
| 2015-12-31 | $187.08 Million | $-92.56 Million | -0.495x | +32.58% |
| 2014-12-31 | $100.48 Million | $-73.74 Million | -0.734x | -133.00% |
| 2013-12-31 | $186.29 Million | $-58.67 Million | -0.315x | +17.45% |
| 2012-12-31 | $114.83 Million | $-43.81 Million | -0.382x | +19.12% |
| 2011-12-31 | $99.88 Million | $-47.12 Million | -0.472x | +52.15% |
| 2010-12-31 | $52.11 Million | $-51.37 Million | -0.986x | +81.27% |
| 2009-12-31 | $6.38 Million | $-33.55 Million | -5.262x | -399.07% |
| 2008-12-31 | $16.16 Million | $-17.04 Million | -1.054x | -28.81% |
| 2007-12-31 | $39.13 Million | $-32.03 Million | -0.819x | -73.81% |
| 2006-12-31 | $79.07 Million | $-37.24 Million | -0.471x | -53.22% |
| 2005-12-31 | $74.36 Million | $-22.86 Million | -0.307x | -151.02% |
| 2004-12-31 | $59.88 Million | $-7.33 Million | -0.122x | -148.62% |
| 2003-12-31 | $-57.20 Million | $-14.41 Million | 0.252x | -0.60% |
| 2002-12-31 | $-56.37 Million | $-14.28 Million | 0.253x | -- |
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more